Insider Selling: PTC Therapeutics (NASDAQ:PTCT) EVP Sells $172,290.24 in Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) EVP Lee Scott Golden sold 2,484 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $69.36, for a total value of $172,290.24. Following the transaction, the executive vice president directly owned 89,944 shares in the company, valued at $6,238,515.84. The trade was a 2.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Lee Scott Golden also recently made the following trade(s):

• On Thursday, January 8th, Lee Scott Golden sold 866 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.45, for a total transaction of $66,205.70.
• On Wednesday, January 7th, Lee Scott Golden sold 642 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.48, for a total transaction of $49,742.16.
• On Tuesday, January 6th, Lee Scott Golden sold 1,340 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.95, for a total transaction of $103,113.00.

PTC Therapeutics Trading Up 1.1%

PTC Therapeutics stock opened at $70.66 on Monday. The firm has a market capitalization of $5.85 billion, a price-to-earnings ratio of 9.13 and a beta of 0.48. The firm’s fifty day moving average price is $74.91 and its two-hundred day moving average price is $68.14. PTC Therapeutics, Inc. has a 1-year low of $35.95 and a 1-year high of $87.50.

PTC Therapeutics (NASDAQ:PTCT) last announced its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($1.46). The business had revenue of $164.68 million during the quarter, compared to the consensus estimate of $281.45 million. PTC Therapeutics had a net margin of 39.44% and a negative return on equity of 362.45%. PTC Therapeutics’s revenue was down 22.7% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.85) EPS. On average, research analysts forecast that PTC Therapeutics, Inc. will post -4.52 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. UMB Bank n.a. bought a new stake in shares of PTC Therapeutics in the 4th quarter worth approximately $26,000. Smartleaf Asset Management LLC grew its holdings in PTC Therapeutics by 101.3% during the third quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 236 shares during the period. Optiver Holding B.V. increased its position in PTC Therapeutics by 96.5% in the third quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 249 shares during the last quarter. Comerica Bank raised its stake in shares of PTC Therapeutics by 868.5% in the third quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 469 shares during the period. Finally, Salomon & Ludwin LLC purchased a new position in shares of PTC Therapeutics during the 4th quarter valued at $41,000.

Key PTC Therapeutics News

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Full-year product and royalty revenue topped guidance and Sephience (sepiapterin) showed strong early commercial uptake (Q4 Sephience revenue $92M; 2025 Sephience revenue $111M). The company also ended 2025 with ~$1.95B in cash, supporting runway for commercialization and R&D. PR Newswire
• Positive Sentiment: Bank of America trimmed its price target from $97 to $93 but maintained a “buy” rating — an analyst endorsement that can temper downside and attract buyers despite the cut. Benzinga
• Neutral Sentiment: Earnings-call transcripts and analyst notes are available to parse management commentary and one‑time vs. structural drivers of the miss; these will be important for judging whether weakness is temporary or persistent. Earnings Call Transcript
• Negative Sentiment: Q4 results materially missed expectations: EPS of ($1.67) vs. consensus ($0.21) and revenue $164.7M vs. $281.5M expected — a large shortfall that directly pressured the stock. Zacks: Q4 miss
• Negative Sentiment: Management set FY‑2026 revenue guidance at $700M–$800M versus Street consensus near $974M — a notable downgrade that reduces near‑term upside and raises questions on commercial demand assumptions. PR Newswire: Guidance
• Negative Sentiment: Regulatory uncertainty increased after PTC withdrew a Translarna NDA, prompting fresh questions about that program’s prospects and potential contribution to future revenue. Yahoo: Translarna article
• Negative Sentiment: Significant insider selling occurred Feb. 17–18 (CEO, CFO, EVP, CAO and other insiders sold shares in multiple filings). While sales can be routine (taxes, diversification), clustered executive sales can be perceived negatively by the market. SEC Form 4 (example)

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of PTC Therapeutics in a research note on Friday. Wells Fargo & Company reduced their price objective on shares of PTC Therapeutics from $93.00 to $86.00 and set an “overweight” rating for the company in a research report on Friday. TD Cowen reiterated a “hold” rating on shares of PTC Therapeutics in a research note on Thursday, January 29th. Citigroup lifted their target price on shares of PTC Therapeutics from $50.00 to $75.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 5th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $90.00 target price on shares of PTC Therapeutics in a report on Thursday, January 8th. Ten equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, PTC Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $80.73.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.